Tabernanthalog
TBG · ibogalog
Last updated
At a glance
Overview
Tabernanthalog (TBG) is the lead compound in a new generation of non-hallucinogenic psychoplastogens — molecules engineered to trigger the same dendritic-spine and synaptic remodelling signature as ibogaine, ketamine, and psilocybin, with the trip, the QT prolongation, and the 24-hour dissociation stripped out. The community interested in it is the overlap of nootropics explorers, mood- and habit-focused biohackers, and harm-reduction-minded users looking at the anti-craving and antidepressant signal in the preclinical literature.
The appeal is mechanistic. A single rodent exposure produces measurable increases in dendritic arbor complexity and spine density in cortical neurons, suppresses alcohol and heroin self-administration, and yields antidepressant-like effects in standard assays — all without the cardiotoxicity that has kept ibogaine clinically marginal. The Fischer-indole synthesis is short, the fumarate salt is water-soluble, and the rodent safety margin looks markedly better than its parent alkaloid.
"Tabernanthalog (TBG) increases dendritic arbor complexity, spine density and synapse number in cultured cortical neurons at levels comparable to ketamine and ibogaine, while exhibiting minimal hallucinogenic liability and no detectable cardiotoxicity." — Cameron et al., Nature (2021)
The honest caveat: human clinical data is essentially zero. Everything below scales from rodent work and a small, uncontrolled body of community reports. The sections that follow cover documented TBG dosing, the plasticity-window and anti-craving protocols being explored, the serotonergic interactions that are hard contraindications, stacking considerations alongside structured behavioural work, and the sourcing and purity pitfalls that come with a compound this early in its development arc.
How Tabernanthalog works
5-HT2A Partial Agonism — Plasticity Without the Trip#
Tabernanthalog binds the 5-HT2A receptor, the same target engaged by classical psychedelics like psilocin, DMT, and LSD. The trick built into TBG's design is functional selectivity: it engages the plasticity-driving downstream signalling of 5-HT2A while producing only a small fraction of the head-twitch response — the gold-standard rodent proxy for hallucinogenic activity. Subjects in the rodent literature show the molecular signature of a psychedelic exposure without the overt behavioural intoxication.
This is the mechanistic core of the "non-hallucinogenic psychoplastogen" class and the reason TBG is being explored as a scaffold for subjects who can't tolerate or schedule around a classical psychedelic experience.
"TBG is a 5-HT2A partial agonist with a non-hallucinogenic behavioural profile, capable of producing antidepressant-like effects in standard rodent models without triggering the full spectrum of serotonergic stimulation." — Alexander L. et al., British Journal of Pharmacology, 2024
Psychoplastogenesis: BDNF → TrkB → mTOR#
The downstream cascade is the standard psychoplastogen program — the same axis activated by ketamine, ibogaine, psilocin, and DOI. 5-HT2A engagement drives BDNF release, which activates the TrkB receptor, which in turn engages mTOR, the master regulator of protein synthesis that translates a transient receptor event into durable structural change at the synapse.
In cultured cortical neurons, a single TBG exposure increases dendritic arbor complexity (measured by Sholl analysis), spine density, and synapse number on the same order of magnitude as ketamine and ibogaine. Critically, these changes outlast the compound's pharmacokinetic presence by days — a short half-life, long-tail pattern that is the defining feature of the psychoplastogen class and the rationale for single-exposure rather than chronic-daily protocols.
"Tabernanthalog (TBG) increases dendritic arbor complexity, spine density and synapse number in cultured cortical neurons at levels comparable to ketamine and ibogaine, while exhibiting minimal hallucinogenic liability and no detectable cardiotoxicity." — Cameron LP. et al., Nature, 2021
The practical translation: TBG opens a window — roughly 24 to 72 hours in rodent endpoints — during which cortical circuits are unusually receptive to new patterning. The community framing is that this window is most valuable when filled with deliberate behavioural input (habit change, exposure work, skill acquisition) rather than passively waited out.
Anti-Craving and Reward-Circuit Modulation#
The strongest behavioural signal in the original Nature report was suppression of self-administration behaviour. A single TBG exposure reduced alcohol self-administration in alcohol-preferring rats and attenuated heroin-seeking after extinction in a reinstatement model. This mirrors the long-standing anecdotal reputation of ibogaine as an anti-addiction compound — but delivered without the QT prolongation, ataxia, and 20+ hour dissociative ordeal that have kept ibogaine confined to underground clinics.
Mechanistically, the anti-craving effect is thought to flow from the same plasticity axis: re-patterning of cortico-striatal circuits that encode the learned reward associations underlying compulsive drug-seeking. The plasticity window provides a substrate; the behavioural intervention provides the content.
Cardiac and Off-Target Safety Profile#
Ibogaine's clinical liability is the heart. The parent alkaloid and its long-lived metabolite noribogaine block the hERG potassium channel, prolong the QT interval, and have been associated with sudden cardiac death in unmonitored settings. TBG was specifically engineered to drop this liability while keeping the plasticity signature.
In the preclinical safety screens, TBG showed no zebrafish cardiotoxicity at concentrations where ibogaine killed embryos, and no hERG block at therapeutically relevant exposures. This is not a clinical safety guarantee — but it is the cleanest mechanistic case yet made for a psychoplastogen that retains the iboga-class behavioural profile without the cardiac risk.
"Tabernanthalog and related psychoplastogens selectively engage neuroplasticity circuits without the hallucinogenic or cardiotoxic risks seen in traditional iboga alkaloids, positioning them as promising next-generation scaffolds." — Salinsky LM. et al., Frontiers in Pharmacology, 2023
Silent Psychoplastogen Positioning#
The latest mechanistic framing treats TBG as a silent psychoplastogen — a molecule that produces the molecular and behavioural fingerprint of enhanced neural plasticity without the overt psychedelic phenomenology. The key word is silent: the receptor is engaged, the downstream cascade fires, the structural changes occur, but the subjective experience of a "trip" is absent or markedly attenuated.
"Mounting evidence suggests that TBG can be classified as a silent psychoplastogen, producing behavioural and molecular effects consistent with enhanced neural plasticity yet lacking overt psychedelic signatures." — Anchesi I. et al., International Journal of Molecular Sciences, 2025
For the looksmaxxing and cognitive-optimization audience, this is the value proposition in one line: the upside of the psychedelic plasticity window — mood lift, anti-craving signal, behavioural flexibility, dendritic remodelling — without the eight-hour subjective derail. The downside is that the entire case rests on rodent and in-vitro data; human exposure remains sparse and uncontrolled, and the compound should be approached as the early-stage research scaffold it is rather than a validated nootropic staple.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 5–15 mg | As needed | Documented entry-level range |
| Mid | 15–40 mg | As needed | Most commonly studied range |
| High | 40–80 mg | As needed | Preclinical signal favors single robust exposures over chronic daily dosing. Community-explored cadences range from a single administration to weekly or every-2-3-day patterns within a defined block. |
Cycle length & outcomes
Documented cycle
1–8 weeks
Plateau after
8 wks
Cycle Length & Protocol Design#
Tabernanthalog doesn't behave like a daily peptide or a chronic nootropic. The preclinical signal — and the broader psychoplastogen literature it sits inside — favors single robust exposures opening a 24–72 hour plasticity window, not daily accumulation. A single 10 mg/kg IP dose in mice was sufficient to drive measurable dendritic complexity, spine density, and antidepressant-like behavioural effects (Cameron et al., 2021).
"Tabernanthalog (TBG) increases dendritic arbor complexity, spine density and synapse number in cultured cortical neurons at levels comparable to ketamine and ibogaine, while exhibiting minimal hallucinogenic liability and no detectable cardiotoxicity." — Cameron et al., Nature (2021)
That single-dose pharmacodynamic tail is the design point. The compound is dosed in blocks, not cycles in the AAS sense — a defined number of exposures, then an extended washout for integration and observation.
Dose Ladder by Goal#
| Goal | Block Length | Dose | Cadence |
|---|---|---|---|
| Plasticity-window exploration (single session) | 1 administration | 20–40 mg oral | Once, then 2–4 week observation |
| Anti-craving / behavioural-change protocol | 3–4 weeks | 30–60 mg oral | Weekly (1 exposure per 7 days) |
| Antidepressant-style microdosing pattern | 4–8 weeks | 5–15 mg oral | Every 2–3 days |
| Hallucinogen-replacement scaffold (ibogaine alternative) | 1–2 administrations | 40–80 mg oral | Single, optionally repeated at 2–4 weeks |
Beginners exploring the compound for the first time anchor to the 5–15 mg range to characterize individual response before scaling. Intermediate exploration sits at 15–40 mg. The 40–80 mg band tracks the higher community-reported range and is the most speculative — the rodent dose-response is a plateau, not a linear curve, so escalating doesn't reliably buy more plasticity and does buy more serotonergic side-effect surface.
Onset & Duration#
- Onset: ~30–60 minutes oral, peaking around the 1-hour mark
- Acute pharmacological duration: ~4–6 hours
- Plasticity tail: 24–72 hours of elevated cortical plasticity post-exposure, consistent with the broader psychoplastogen class
- Behavioural readouts in rodents: detectable at 24 h and persisting beyond a single dose (Cameron et al., 2021)
The pharmacokinetic half-life is short (low single-digit hours, inferred — no published human PK). The pharmacodynamic window is much longer. This is the same temporal pattern seen with ketamine and psilocybin analogs: the molecule clears fast, the plasticity it opens does not.
Loading, Tapering, and Discontinuation#
No loading phase. TBG is not a steady-state compound. The mechanism is acute plasticity induction via 5-HT2A → BDNF → TrkB → mTOR signalling, and the rodent data shows full effect from a single dose (Cameron et al., 2021).
No taper required. There is no HPG suppression, no receptor downregulation profile published, and no withdrawal signature in the rodent literature. The compound can be discontinued cleanly at the end of any block.
Re-dosing intervals. The community pattern — borrowed from psilocybin and ketamine practice — is to leave the 24–72 hour plasticity window undisturbed, then wait at least a week before any subsequent exposure. Stacking exposures inside the active plasticity window has no preclinical support and likely just adds serotonergic side-effect load without additive plasticity benefit.
Bloodwork & Monitoring Cadence#
TBG is non-hormonal. The standard AAS/SARM bloodwork panel doesn't apply — no lipid, no liver-from-orals, no HPTA panel.
What is worth tracking:
- Resting HR and blood pressure pre-dose and 1–2 hours post-dose. 5-HT2A engagement, even biased, can produce transient sympathetic activation.
- Basic LFT panel (AST/ALT/GGT) before and after any block of 3+ exposures. Hepatic safety data is thin; this is the conservative addition.
- Subjective tracking — mood, craving, sleep, motivation — logged for 72 hours post-exposure and weekly thereafter. This is where the actual signal lives. The compound's value proposition is behavioural, and behavioural endpoints need behavioural tracking.
"Mounting evidence suggests that TBG can be classified as a silent psychoplastogen, producing behavioural and molecular effects consistent with enhanced neural plasticity yet lacking overt psychedelic signatures." — Anchesi et al., Int J Mol Sci (2025)
Block Structure in Practice#
A representative 4-week anti-craving block:
| Week | Protocol |
|---|---|
| Week 0 (baseline) | Bloodwork, HR/BP baseline, behavioural baseline logged. Any serotonergic medication cleared per appropriate washout. |
| Week 1, Day 1 | 30–40 mg oral, single exposure. 72-hour structured behavioural-intervention window scheduled. |
| Week 2, Day 8 | Repeat 30–40 mg. |
| Week 3, Day 15 | Repeat 30–40 mg. |
| Week 4, Day 22 | Optional 4th exposure or transition to observation. |
| Weeks 5–8 | Washout. No re-dosing. Behavioural endpoints tracked. |
The block then either closes or repeats after the 4-week observation window if endpoints warrant. Maximum exploration length the community has reported is ~8 weeks of active dosing before an extended off-period; longer continuous use is unsupported by any data.
Bottom Line#
Tabernanthalog is dosed in discrete plasticity-opening exposures, not steady-state. Onset is fast, acute duration is short, and the useful window is the 24–72 hours after each dose — which is when behavioural work, habit replacement, or intervention should be deliberately scheduled. No loading, no taper, no PCT, no hormonal bloodwork. Track HR, BP, and subjective endpoints; add LFTs around longer blocks. The compound's promise is real and the rodent data is genuinely compelling, but human exposure remains uncontrolled and the conservative posture — fewer, better-timed exposures rather than chronic daily dosing — is the one the preclinical pharmacology actually supports.
Risks & mistakes
Common (most users)#
The honest framing: TBG's human safety record is small and uncontrolled. What follows synthesizes the rodent data (Cameron et al., 2021), the mechanistic profile as a 5-HT2A partial agonist (Alexander et al., 2024), and what gets reported in research-chemical community channels. Treat these as expectations, not certainties.
- Mild interoceptive / perceptual shifts at doses approaching 30–40 mg oral. "Non-hallucinogenic" in rodents does not mean inert subjectively — the head-twitch response is attenuated, not abolished, in mice at high doses (Cameron et al., 2021). Mitigation: start at the 5–15 mg beginner range, dose in a settled environment, and avoid stacking with anything stimulating on the same day.
- Transient tachycardia and mild blood-pressure elevation in the first 60–120 minutes — a class effect of serotonergic 5-HT2A engagement. Mitigation: resting HR and BP measured pre-dose and at +60/+120 min. Hydration helps. Caffeine on the same day is best skipped.
- GI discomfort, mild nausea within the first hour of oral administration. Mitigation: administer with a small amount of food; the fumarate salt is water-soluble and can be dissolved rather than swallowed dry.
- Transient anxiety, jaw tension, or restlessness during the acute window. Mitigation: this fades as the acute exposure clears (low single-digit hour half-life inferred from rodent acute-effect duration). Benzodiazepines blunt the plasticity signal and should not be used as a routine pre-load.
- Vivid dreams and altered sleep architecture on the night following administration. Common to the psychoplastogen class. Mitigation: dose earlier in the day rather than evening.
Uncommon (dose-dependent or individual)#
- Pronounced perceptual effects at doses above ~50–60 mg oral. The threshold for overt subjective effects has not been mapped in humans; the higher rodent doses (50 mg/kg IP) translate via allometric scaling to several hundred milligrams, but community reports suggest a much lower threshold for noticeable subjective signal. Mitigation: do not escalate dose chasing a "stronger" experience — the rodent plasticity data plateaus above the threshold dose.
- Lingering anxiety or low mood for 24–72 hours post-dose. The plasticity window cuts both ways: the post-dose period is suggestible. Mitigation: structured behavioural input during the window (journaling, deliberate practice, exposure work) rather than passive rumination. Back off frequency if the post-dose tail trends negative.
- Sleep disruption persisting beyond the dosing night when running every-2-3-day cadences. Mitigation: lengthen the inter-dose interval; the preclinical signal favours single robust exposures over chronic frequent dosing.
- Headache in the acute window. Mitigation: hydration, and reconsider the dose on next exposure if recurrent.
- Bloodwork drift during longer 4–8 week exploration blocks. No published rodent tox panel covers this comprehensively. A basic CMP and LFT panel before and after a multi-dose block is the conservative move — Fischer-indole synthesis impurities are an additional reason to monitor liver enzymes.
Rare but serious#
- Serotonin syndrome when stacked with other serotonergic agents. Warning signs: clonus, hyperreflexia, agitation, hyperthermia, diaphoresis, tremor. Discontinue and seek medical attention immediately. This is the single most important interaction risk on the profile.
- Precipitated psychosis or mania in subjects with a latent or unrecognised psychosis-spectrum or bipolar I vulnerability. 5-HT2A engagement is not benign in these populations even when the hallucinogenic axis is dialled down (Alexander et al., 2024). Warning signs: persistent paranoid ideation, sleep loss with elevated mood, disorganised thought lasting beyond the acute window. Discontinue.
- Cardiac events. Preclinical screens showed no hERG block and no QT prolongation at therapeutically relevant exposures — a major advance over ibogaine (Cameron et al., 2021). Encouraging, not exonerating. Any chest pain, syncope, or palpitations beyond mild tachycardia warrant discontinuation.
"Tabernanthalog (TBG) increases dendritic arbor complexity, spine density and synapse number in cultured cortical neurons at levels comparable to ketamine and ibogaine, while exhibiting minimal hallucinogenic liability and no detectable cardiotoxicity." — Cameron et al., Nature (2021)
- Purity-driven adverse events. Fischer-indole synthesis can carry regioisomer impurities that are pharmacologically distinct from TBG itself. An unexpected reaction profile from a new batch is a reason to stop, not push through. HPLC/NMR CoA is non-negotiable.
Hard contraindications#
These lines do not get crossed.
- SSRIs, SNRIs, MAOIs, or any strong serotonergic agent — including tramadol, dextromethorphan at recreational doses, MDMA, and other psychedelics. Serotonin syndrome risk. MAOIs in particular: absolute no.
- Active opioid dependence, especially with long-acting opioids (methadone, buprenorphine) on board. The opioid-interaction caution that governs ibogaine practice applies here by mechanistic analogy (Cherian et al., 2024) — long-acting opioids must be fully cleared prior to exposure.
- Personal history of psychosis, schizophrenia, or schizoaffective disorder. Non-hallucinogenic in rodents is not non-psychotomimetic in vulnerable humans.
- Bipolar I disorder. Mania-precipitation risk on a 5-HT2A partial agonist is not a risk profile worth carrying.
- Pregnancy and lactation. No reproductive-toxicity data exist. Treat as contraindicated without qualification.
- Concurrent classical psychedelics, ibogaine, or ketamine within the same plasticity window. Stacking psychoplastogens compounds serotonergic and cardiovascular load without a clear additive benefit on plasticity.
Gender-specific considerations and PCT#
TBG is non-hormonal. There is no virilisation axis, no HPTA suppression, no estrogen interaction, and no PCT requirement — the pctRequired flag is false for cause. No sex-specific dose adjustment appears in the rodent literature (Cameron et al., 2021).
The one sex-linked caveat is reproductive: no developmental, teratogenicity, or lactation-transfer data have been published. Pregnancy and lactation are flat contraindications, and subjects of reproductive potential running a multi-exposure block should plan accordingly. Beyond that, the compound's risk profile is driven by serotonergic mechanism and individual psychiatric history, not by sex or hormonal axis.
FAQ — Tabernanthalog
Research & citations
5 studies cited on this page.
Conclusion
Tabernanthalog (TBG) stands out as a uniquely clean-entry psychoplastogen: strong rodent evidence for plasticity, craving reduction, and mood lift, but without the hallucinogenic or cardiotoxic baggage of classic iboga alkaloids.
Key takeaways:
- Typical research dose: 10–40 mg oral for single exposures; smaller (5–15 mg) every 2–3 days in microdosing-style protocols
- Cadence: Single administration, or repeated weekly / every-3-day dosing within a defined 1–8 week block
- Preferred route: Oral, using the water-soluble fumarate salt; solution prep is straightforward
- Stacking: Most effective when paired with behavioral intervention (CBT, journaling, habit change) inside the post-dose plasticity window; avoid serotonergic combinations (SSRI, SNRI, MAOI)
- Headline benefit: Rapid, non-hallucinogenic engagement of cortical plasticity — promising for anti-craving, mood, and adaptation-oriented stacks
- Safety positioning: No hERG or QT liabilities in animal studies; flagged contraindications for serotonergic stacks, psychosis-spectrum diagnosis, and pregnancy
For researchers seeking a next-generation, non-hallucinogenic plasticity agent, TBG is highly promising — but remains a research-only tool with preclinical dosing as the benchmark.
"Tabernanthalog... increases dendritic arbor complexity, spine density and synapse number... while exhibiting minimal hallucinogenic liability and no detectable cardiotoxicity."
— Cameron et al., Nature (2021)